

Additional file 2 — Results of the stratified Cox model after exclusion of the 37 STR also included in FTR, based on 2713 patients with 2206 FTR and 507 STR (22 STR presenting missing data for the waiting time before re-transplantation were excluded)

	FTR strata			STR strata		
	HR	95% CI	p-value	HR	95% CI	p-value
Variables entering in z^e only						
Causal nephropathy (recurrent / non recurrent)	1.13	0.91-1.40	0.2792	-	-	-
History of diabetes (positive / negative)	1.26	0.93-1.69	0.1330	-	-	-
History of hypertension (positive / negative)	0.89	0.68-1.15	0.3593	-	-	-
History of cardiac disease (positive / negative)	1.36	1.10-1.67	0.0041	-	-	-
History of vascular disease (positive / negative)	1.13	0.85-1.49	0.3949	-	-	-
History of dyslipemia (positive / negative)	1.20	0.96-1.51	0.1174	-	-	-
History of hepatitis B/C (positive / negative)	0.98	0.65-1.47	0.9263	-	-	-
History of malignancy (positive / negative)	1.20	0.86-1.68	0.2744	-	-	-
Body mass index (≥ 30 kg.m-2 / < 30 kg.m-2)	1.53	1.13-2.08	0.0066	-	-	-
Anti-class I PRA (positive / negative)	1.43	1.09-1.87	0.0090	-	-	-
Anti-class II PRA (positive / negative)	0.98	0.73-1.31	0.8761	-	-	-
Donor status (deceased/living)	2.04	1.25-3.32	0.0042	-	-	-
Donor EBV serology (positive / negative)	1.66	1.08-2.55	0.0219	-	-	-
Number of HLA-A-B-DR mismatches (> 4 / ≤ 4)	1.34	1.02-1.77	0.0345	-	-	-
Induction therapy (depleting / non depleting)	0.89	0.71-1.12	0.3138	-	-	-
Cold ischemia time (≥ 24 h / < 24 h)	1.22	0.99-1.51	0.0656	-	-	-
Variables entering in z^c and z^s						
Transplantation period (< 2005 / ≥ 2005)	1.41	1.08-1.85	0.0113	0.99	0.56-1.74	0.9848
Recipient gender (male / female)	1.17	0.91-1.50	0.2112	0.64	0.39-1.03	0.0664
Recipient age (≥ 55 years / < 55 years)	1.36	1.04-1.78	0.0271	1.48	0.86-2.53	0.1564
Donor age (≥ 55 years / < 55 years)	1.36	1.04-1.77	0.0238	0.62	0.35-1.09	0.0725
Variables entering in z^r only						
Donor gender (male / female)	-	-	-	1.47	0.94-2.31	0.0941
Waiting time before regraft ≥ 3 years	-	-	-	1.90	1.22-2.97	0.0047

PRA, panel reactive antibody; EBV, Epstein-Barr virus; HLA, human leukocyte antigen